Recent advances in ph-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy

Current Drug Targets

Volumn 17, Issue 16, 2016, Pages

  Lim, Eun Kyung ^a   Chung, Bong Hyun ^a,b   Chung, Sang J ^c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Dongguk University   (South Korea)

Author keywords

Cancer therapy; Drug carrier; Drug delivery; Nanoparticle; Nanotechnology; pH sensitive; Theranostics

Indexed keywords

AMPHOTERICIN B; BEVACIZUMAB; CETUXIMAB; CYCLODEXTRIN; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GOLD NANOPARTICLE; LIPOSOME; MACROGOL NANOPARTICLE; MANGANESE OXIDE NANOPARTICLE; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; PLGA PEG NANOPARTICLE; PROTEIN P53; RITUXIMAB; SHORT HAIRPIN RNA; SILICA NANOPARTICLE; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE; VINORELBINE TARTRATE; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; BIODEGRADABILITY; BREAST CANCER; CANCER THERAPY; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; GASTROINTESTINAL CARCINOMA; HUMAN; IMMUNOGENICITY; KAPOSI SARCOMA; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MONONUCLEAR PHAGOCYTE; MYCOSIS; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PANCREAS CANCER; PH; REVIEW; SOLID TUMOR; THERANOSTIC NANOMEDICINE; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DELAYED RELEASE FORMULATION; NEOPLASM;

DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; NANOPARTICLES; NEOPLASMS; THERANOSTIC NANOMEDICINE;

EID: 84994900724     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450117666160602202339     Document Type: Review

References (150)

1. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater 2011; 23: H217-47.
2. Lim EK, Kim T, Paik S, Haam S, Huh YM, Lee K. Nanomaterials for theranostics: Recent advances and future challenges. Chem Rev 2015; 115: 327-94.
3. Haam S, Lee K, Yang J, Huh Y-M. In: Nanomaterials for the life science Vol 8 Nanocomposites Kumar C, Ed 2010; Vol. 8; pp. 273-95.
4. Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 2013; 5: 216-4.
5. Lim E-K, Jang E, Lee K, Haam S, Huh Y-M. Delivery of cancer therapeutics using nanotechnology. Pharmaceutics 2013; 5: 294-317.
6. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorgan Med Chem 2009; 17: 2950-62.
7. Shi J, Vortuba AR, Farokhzad OC, Langer R. Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to applications. Nano letters 2010; 10: 3223-30.
8. Ficai D, Sonmez M, Albu MG, Mihaiescu DE, Ficai A, Bleotu C. Antitumoral materials with regenerative function obtained using a layer-by-layer technique. Drug Des Dev Ther 2015; 9: 1269-79.
9. Marques C, Ferreira J MF, Andronescu E, Ficai D, Sonmez M, Ficai A. Multifunctional materials for bone cancer treatment. Int J Nanomedicine 2014; 9: 2713-25.
10. Rosler A, Vandermeulen GWM, Klok H-A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001; 53: 95-108.
11. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
12. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surface B 2010; 75: 1-18.
13. Menon JU, Kona S, Wadajkar AS, Desai F, Vadla A, Nguyen KT. Effects of surfactants on the properties of PLGA nanoparticles. J Biomed Mater Res A 2012; 100A: 1998-2005.
14. Soussan E, Cassel S, Blanzat M, Rico-Lattes I. Drug delivery by soft matter: Matrix and Vesicular carriers. Angew Chem Int Ed 2009; 48: 274-88.
15. Chacko RT, Ventura J, Zhuang J, Thayumanavan S. Polymer nanogels: A versatile nanoscopic drug delivery platform. Adv Drug Deliv Rev 2012; 64: 836-51.
16. Zhang K, Tang X, Zhang J, et al. PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications. J Control Release 2014; 183: 77-86.
17. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999; 57: 171-85.
18. Unsoy G, Gunduz U, Oprea O, et al. Magnetite: from synthesis to applications. Curr Top Med Chem 2015; 15: 1622-40.
19. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66: 2-25.
20. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Release 2010; 148: 135-46.
21. Deepthi A, Raju S, Kalyani A, Udaya Krian M, Vanaja A. Targeted Drug delivery to the nucleus and its potential role in cancer chemotherapy. J Pharm Pharm Sci 2013; 5: 48-56.
22. Ryu JH, Koo H, Sun I-C, et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev 2012; 64: 1447-58.
23. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 2010; 62: 284-304.
24. Barreto JA, O’Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: Applications in cancer imaging and therapy. Adv Healthc Mater 2011; 23: H18-H40.
25. Zheng J, Muhanna N, Souza RD, et al. A multimodal nano agent for image-guided cancer surgery. Biomaterials 2015; 67: 160-8.
26. Khemtong C, Kessinger CW, Gao J. Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun 2009; 28: 3497-510.
27. Pene F, Courtine E, Cariou A, Mira J-P. Toward theranostics. Crit Care Med 2009; 37: S50-S8.
28. Kim K, Kim JH, Park H, et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 2010; 146: 219-27.
29. Huang Y, He S, Cao W, Cai K, Liang X-J. Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale 2012; 4: 6135-49.
30. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012; 2: 3-44.
31. Vierken LE, amiji MM. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006; 3: 205-16.
32. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotech 2007; 2: 751-60.
33. Larson N, Ghandehari H. Polymeric conjugates for drug dlelivery. Chem Mater 2012; 24: 840-53.
34. Yang W-W, Pierstorff E. Reservoir-based polymer drug delivery systems. J Lab Autom2012; 17: 50-8.
35. Torchilin V. Tumor delivery of macromolecular drugs based on EPR effect. Adv Drug Deliv Rev 2011; 63: 131-5.
36. Harris JM, Chess RB. Effect of pegylation on pharamaceuticals. Nat Rev 2003; 2: 214-21.
37. Veronese FM, Pasut G. PEGylation, successgul approach to drug delivery. Drug Discov Today 2005; 10: 1451-8.
38. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 2010; 49: 6288-308.
39. Grefa R, Lückb M, Quellecc P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surface B 2000; 18: 301-13.
40. Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drug. Biomaterials 2005; 26: 2713-22.
41. Abad JM, Mertens SFL, Pita M, Fernández VM, Schiffrin DJ. Functionalization of thioctic acid-capped gold nanopartciels for specific immobilization of histidine-tagged proteins. J Am Chem Soc 2005; 127: 5689-94.
42. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 2009; 131: 2072-3.
43. Yang J, Lee J, Kang J, et al. Hollow silica nanocontainers as drug delivery vehicles. Langmuir 2008; 24: 3417-21.
44. Yavuz MS, Cheng Y, Chen J, et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater 2009; 8: 935-9.
45. Jung J, Solanki A, Memoli KA, et al. Selective Inhibition of Human Brain Tumor Cells through Multifunctional Quantum-Dot-Based siRNA Delivery. Angew Chem Int Ed 2010; 49: 103-7.
46. Ng VWK, Berti R, Lesage F, Kakkar A. Gold: a versatile tool for in vivo imaging. J Mater Chem B 2013; 1: 9-25.
47. Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release 2010; 148: 122-7.
48. Wang F, Wang Y-C, Dou S, Xiong M-H, Sun T-M, Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011; 5: 3679-92.
49. Kang J, Yang J, Lee J, et al. Gold-layered calcium phosphate plasmonic resonants for localized photothermal treatment of human epithelial cancer. J Mater Chem 2009; 19: 2902-5.
50. Phan VN, Lim E-K, Kim T, et al. A highly crystalline manganesedoped iron oxide nanocontainer with predesighned void volume and shape for theranostic applications. Adv Mater 24; 25: 3202-8.
51. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20.
52. Mansour HM, Park CW, Bawa R. In: Handbook of Clinical Nanomedicine-From Bench to Bedside; Bawa R, Audette G, Rubinstein I, Eds. Singapore: Pan Stanford Publishing 2014; pp. 1-40.
53. Gullotti E, Yeo T. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 2009; 6: 1041-51.
54. Martina M-S, Fortin J-P, Ménager C, et al. Generation of Superparamagnetic Liposomes Revealed as Highly Efficient MRI Contrast Agents for in vivo Imaging. J Am Chem Soc 2005; 127: 10676-85.
55. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001; 73: 137-72.
56. Kopecek J. Polymer-drug conjugates: origins, process to date and future directions. Adv Drug Deliv Rev 2013; 65: 49-59.
57. Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 2007; 32: 933-61.
58. Siddique AB, Cho Y, Kim Y, et al. pH-Sensitive Drug-Conjugates on Water-Soluble Polymer Frameworks. Macromol Chem Physic 2015; 216: 265-76.
59. Veronese FM, Schiavon O, Pasut G, et al. PEG−Doxorubicin Conjugates: Influence of Polymer Structure on Drug Release, in vitro Cytotoxicity, Biodistribution, and Antitumor Activity. Bioconjugate Chem 2005; 16: 775-84.
60. Rowinsky EK, Rizzo J, Ochoa L, et al. A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies. J Clinic Oncol 2003; 21: 48-157.
61. Scott LC, Evans T, Yao JC, et al. Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study. J Clinic Oncol 2004; 22 (14_suppl): 4030.
62. Cheng J, Teply BA, Sherifia I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007; 28: 869-76.
63. Yang X, Grailer JJ, Rowland IJ, et al. Multifunctional Stable and pH-Responsive Polymer Vesicles Formed by Heterofunctional Triblock Copolymer for Targeted Anticancer Drug Delivery and Ultrasensitive MR Imaging. ACS Nano 2010; 4: 6805-17.
64. Yang J, Cho E-J, Seo S, et al. Enhancement of cellular binding efficiency and cytotoxicity using polyethylene glycol base triblock copolymeric nanoparticles for targeted drug delivery. J Biomed Mater Res A 2008; 84A: 273-80.
65. Hu Z, Luo F, Pan Y, et al. Arg-Gly-Asp (RGD) peptide conjugated poly (lactic acid)-poly (ethylene oxide) micelle for targeted drug delivery. J Biomed Mater Res A 2008; 85A: 797-807.
66. Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. P Natl Acad Sci USA 2008; 105: 9343-8.
67. Xiong X-B, Huang Y, Lu W-l, Zhang H, Zhang X, Zhang Q. Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in vitro Resulting in Improved Antitumor Activity in vivo. Pharmaceut Res 2005; 22: 933-9.
68. Xiong X-B, Huang Y, LU W-L, et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: In vitro and in vivo. J Pharm Sci 2005; 94: 1782-93.
69. Kim E, Yang J, Kim H-O, et al. Hyaluronic acid receptortargetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. Biomaterials 2013; 34: 4327-38.
70. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric ddoxorubicin micelles. J control Release 2004; 96: 273-83.
71. Grillo-López AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66-73.
72. Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs today 1999; 35: 931-46.
73. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35.
74. Cutsem EV, Köhne C-H, Hitre E, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New Engl J Med 2009; 360: 1408-17.
75. Yang T, Choi M-K, Cui F-D, et al. Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cell. Pharmaceut Res 2007; 24: 2402-11.
76. Mamot C, Drummond DC, Noble CO, et al. Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs In vivo. Cancer Res 2005; 65: 11631-8.
77. Lim E-K, Huh Y-M, Yang J, Lee K, Suh J-S, Haam S. pHtriggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Adv Mater 2011; 23: 2436-42.
78. Kim E, Jung Y, Choi H, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010; 31: 4592-9.
79. Bartlett DW, Davis ME. Insights into the kinetics of siRNAmediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006; 34: 322-33.
80. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004; 96: 273-83.
81. Jang E, Lim E-K, Choi Y, et al. pi-hyaluronan nanocarriers for CD44-targeted and pH-boosted aromatic drug delivery. J Mater Chem B 2013; 1: 5685-93.
82. Eliaz RE, Nir S, Marty C, Szoka FC. Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes. Cancer Res. 2004; 64: 711-8.
83. Baselga J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2010; 25: 592-8.
84. Laginha KM, Moase EH, Yu N, Huang A, Allen TM. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J Drug Target. 2008; 16: 605-10.
85. Yang J, Lee J, Jang J, et al. Smart drug-loaded polymer gold nanoshells for systemic and localized therapy of human epithelial cancer. Adv Mater. 2009; 21: 4339-42.
86. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005; 65: 11631-8.
87. Frens MHA, Hill KJ, Issa J, et al. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer. 2008; 99: 1256-64.
88. Yu K-F, Zhang W-Q, Luo L-M, et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine. 2013; 8: 2473-85.
89. Hu Z, Luo F, Pan Y, Hou C, et al. Arg-Gly-Asp (RGD) peptide conjugated poly (lactic acid)-poly (ethylene oxide) micelle for targeted drug delivery. J Biomed Mater Res A. 2008; 85: 797-807.
90. Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA. 2008; 105: 9343-8.
91. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007; 28: 869-76.
92. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006; 103: 6315-20.
93. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA. 2008; 105: 2586-91.
94. Gosk SI, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta. 2008; 1778: 854-63.
95. Kondo M, Asai T, Katanasaka Y, et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer. 2004; 108: 301-6.
96. Traitel T, Goldbart R, Kost J. Smart polymers for responsive drugdelivery systems. Acta Pharm Sin B 2008; 19: 755-67.
97. James HP, John R, Alex A, K.R. A. Smart polymers for the controlled delivery of drugs-a concise overview. Acta Pharm Sin B 2014; 4: 120-7.
98. Timko BP, Dvir T, Kohane DS. Remotely triggerable drug delivery systems. Adv Mater 2010; 22: 4925-43.
99. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 2006; 384: 620-30.
100. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013; 12: 991-1002.
101. Fleige E, Quadir mA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications. Adv Drug Deliv Rev 2012; 64: 866-84.
102. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Red 2006; 66: 5216-23.
103. Aluri S, Janib SM, Mackay A. Environmentally responsive peptides as anticancer drug carriers. Adv Drug Deliv Rev 2009; 61: 940-52.
104. Chan A, Orme RP, Fricker RA, Roach P. Remote and local control of stimuli responsive materials for therapeutic applications. Adv Drug Deliv Rev 2013; 65: 497-514.
105. Fattal E, Couvreur P, Dubernet C. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 2004; 56: 931-46.
106. Felber AE, Dufresne m-H, Leroux J-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliv Rev 2012; 64: 979-92.
107. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001; 53: 321-39.
108. Sato K, Yoshida K, Takahashi S, Anzai J-i. pH-and sugar-sensitive layer-by-layer films and microcapsules for drug delivery. Adv Drug Deliv Rev 2011; 63: 809-21.
109. Auguste DT, Armes SP, Brezinska KR, Deming TJ, Kohn J, Orud'homme RK. pH triggered release of protective poly (ethylene glycol)-b-polycation copolymers from liposomes. Biomaterials 2006; 27: 2599-608.
110. Shi Q, Zhang L, Liu M, et al. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derivednanomedicine in drug resistant cancer cells. Biomaterials 2015; 67: 169-82.
111. Yuba E, Kanda Y, Yoshizaki Y, et al. pH-sensitive polymerliposome-based antigen delivery systems potentiated with inteferon-gama gene lipoplex for efficient cancer immunotherapy. Biomaterials 2015; 67: 214-24.
112. Liu J, Huang Y, Tan A, Jin S, Mozhi A, Liang X-J. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotech Adv 2014; 32: 693-710.
113. Du J-Z, Du X-J, Mao C-Q, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc 2011; 133: 17560-3.
114. Huh KM, Kang HC, Lee YJ, Bae YH. pH-sensitive polymers for drug delivery. Macromol Res 2012; 20: 224-33.
115. Alvarez-Lorenzo C, Blanco-Fernandez B, Puga AM, Concheiro A. Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery. Adv Drug Deliv Rev 2013; 65: 1148-71.
116. Liu Y, Wang W, Yang J, Zhou C, Sun H. pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery. Aisan J Chem 2013; 8: 159-67.
117. Alvarez-Lorenzo C, Concheiro A. Smart drug delivery systems: from fundamentals to the clinic. Chem Commun 2014; 50: 7743-65.
118. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog Polym Sci 2007; 32: 962-90.
119. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed 2003; 42: 4640-3.
120. Galande AK, Weissleder R, Tung C-H. Fluorescence probe with a pH-sensitive trigger. Bioconjugate Chem 2006; 17: 255-7.
121. Mok H, Park JW, Park TG. Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal Bioconjugate Chem 2008; 19: 797-801.
122. Alani AWG, Bae Y, Rao DA, Kwon GS. Polymeric micelles for the pH-dependent controlled, continous low dose release of paclitaxel. Biomaterials 2010; 31: 1765-72.
123. Lin Y-K, Jiang G, Birrell LK, El-Sayed KEH. Degradable, pHsensitive, membrane-destabilizing, comb-like polymers for intracellular delivery of nucleic acids. Biomaterials 2010; 31: 7150-66.
124. Gillies ER, Frechet JMJ. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate Chem 2005; 16: 361-8.
125. Du Y, Chen W, Zheng M, Meng F, Zhong Z. pH-sensitive degradable chimaeric polymersomes for the intracellular release of doxorubicin hydrochloride. Biomaterials 2012; 33: 7291-9.
126. Liu Z, Zheng M, Meng F, Zhong Z. Non-viral gene transfection in vitro using endosomal pH-sensitive reversibly hydrophobilized polyehyleneimine. Biomaterials 2011; 32: 9109-19.
127. Chen W, Meng F, Cheng R, Zhong Z. pH-sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles. J Control Release 2010; 142: 40-6.
128. Benns JM, Choi J-S, Mahato RI, Park J-S, Kim SW. pH-Sensitive Cationic Polymer Gene Delivery Vehicle: N-Ac-poly (l-histidine)-graft-poly (l-lysine) Comb Shaped Polymer. Bioconjugate Chem 2000; 11: 637-45.
129. Toriyabe N, Hayashi Y, Harashima H. The transfection activity of R8-mediated nanoparticles and siRNA condensation using pH sensitive stearylated octahistidine. Biomaterials 2013; 34: 1337-43.
130. Wu H, Zhu L, Torchilin VP. pH-sensitive poly (histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials 2013; 34: 1213-22.
131. Liu R, Li D, He B, et al. Anti-tumor drug delivery of pH-sensitive poly (ethylene glycol)-poly (l-histidine-)-poly (l-lactide) nanoparticles. J Control Release 2011; 152: 49-56.
132. Schmaljohann D. Thermo-and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 2006; 58: 1655-70.
133. Lim KS, Lee DY, Valencia GM, Won Y-W, Bull DA. Nano-selfassembly of nucleic acids capable of transfection without a gene carrier. Adv Funct Mater 2015.
134. Ding C, Gu J, Yang Z. Preparation of multifunctional drug carrier for tumor-specific uptake and enhanced intracellular delivery through the conjugation of weak acid labile linker. Bioconjugate Chem 2009; 20: 1163-70.
135. Kolli S, Wong S-P, Harbottle R, Johnston B, Thanou M, Miller AD. pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo. Bioconjugate Chem 2013; 24: 314-32.
136. Seo S-B, Yang J, Hyung W, et al. Novel multifunctional PHDCA/PEI nano-drug carriers for simultaneous magnetically targeted cancer therapy and diagnosis via magnetic resonance imaging. Nanotechnology 2007; 18: 475105-13.
137. Yu MK, Kim D, Lee I-H, So J-S, Jeong YY, Jon S. Image-Guided Prostate Cancer Therapy Using Aptamer-Functionalized Thermally Cross-Linked Superparamagnetic Iron Oxide Nanoparticles. Small 2011; 7: 2241-9.
138. Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Kann B, Dijk WJ, Thijssen VL, Griffioen AW, Storm G, Fayad ZA, Mulder WJ. A Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. ACS Nano 2011; 5: 4422-33.
139. Yang J, Lee C-H, Ko H-J, et al. Multifunctional magnetopolymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed 2007; 46: 8836-9.
140. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010; 31: 3694-706.
141. Boles KS, Schimieder AH, Koch AW, et al. MR angiogenesis imaging with Robo4-vs. αVβ3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 2010; 24: 4262-70.
142. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/Due-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/MR-imaging. Small 2009; 5: 1862-68.
143. Lim E-K, Sajomsang W, Choi Y, et al. Chitosan-based intelligent intelligent theragnosis nanocomposites enable pH-sensitive drug release with MR-guided imaging for cancer therapy. Nanoscale Res Lett 2013; 8: 467-78.
144. Kim E, Lee H, An Y, et al. Imidazole magnetic nanovectors with endosome disrupting moieties for the intracellular delivery of imaging of siRNA. J Mater Chem B 2014; 2: 8566-75.
145. Gao GH, Li Y, Lee DS. Environmental pH-sensitive polymeric micelles for cancer diagnosis and targeted therapy. J Control Release 2013; 169: 180-4.
146. Guo M, Que C, Wang C, Liu X, Yan H, Liu K. Mutifunctional superparamanetic nanocarriers with folate-mediated and pHresponsive targeting properties for anticancer drug delivery. Biomaterials 2011; 32: 185-94.
147. Liu B, Chen Y, Li C, et al. Poly (Acrylic Acid) Modification of Nd3+-Sensitized Upconversion Nanophosphors for Highly Efficient UCL Imaging and pH-Responsive Drug Delivery. Adv Funct Mater 2015; 25: 4717-29.
148. Das M, Mishra D, Dhak P, et al. Biofunctionalized, Phosphonate-Grafted, Ultrasmall Iron Oxide Nanoparticles for Combined Targeted Cancer Therapy and Multimodal Imaging. Small 2009; 5: 2883-93.
149. Banerjee SS, Chen D-H. Multifunctional pH-sensitive magnetic nanoparticles for simultaneous imaging, sensing and targeted intracellular anticancer drug delivery. Nanotechnology 2008; 19: 505104.
150. Li L, Li H, Chen D, et al. Preparation and characterization of quantum dots coated magnetic hollow spheres for magnetic fluorescent multimodal imaging and drug delivery. J Nanosci Nanotechnol 2009; 9: 2540-5.